Why BELLUS Health (TSX:BLU) Stock Jumped 30% on the TSX Today!

BELLUS (TSX:BLU)(NASDAQ:BLU) stock went stratospheric with the promise of a new drug that could boost fourth-quarter revenue.

| More on:
healthcare pharma

Image source: Getty Images

Shares of BELLUS Health (TSX:BLU)(NASDAQ:BLU) went gangbusters on the TSX today after management announced “positive findings” in a treatment for refractory chronic cough (RCC). Shares of the company jumped 30% by early Tuesday afternoon and continue to climb.

What happened?

The announcement by BELLUS stock management stated that at least one dose of its BLU-5937 — or SOOTHE — would reduce RCC over a 24-hour period. The 240 participants who had more than 25 awake coughs per hour to see whether there would be a reduction.

RCC would be a cough that lasts more than eight weeks, even with treatment for other conditions. It’s expected about nine million people currently suffer from RCC in the United States alone. Right now, there aren’t approved therapies for RCC. With phase two complete, phase three is underway for final results. Management believes it can therefore have data available for fourth quarter of 2021.

So what?

There has been a massive shift in the past few months in the health sector on the TSX today. With a vaccine for COVID-19 available, Big Pharma wants the next big thing. And that could very well be BLU-5937. With no serious side affects and a treatment for both a physically and mentally demanding condition, this could be a major bread winner for BELLUS stock.

Analysts agree. Several analysts upgraded BELLUS stock overnight after the strong results of the treatment. Analysts believe further growth could very well be on the way in the immediate future. There is a limited number of treatments, if any, for patients with RCC. So, this is an untapped market right now that BELLUS stock has discovered — one Motley Fool investors should watch carefully.

Analysts now believe BELLUS stock is a buy, with the average share price rising to $10.70, as of writing. That would be a potential upside at writing of a further 49% over the next year. Even with other companies being first to market, BLU-5937 looks to be the best option with no serious risks.

Now what?

Motley Fool investors seeking the next strong stock have likely already had their eye on the health sector. BELLUS stock not only could be a great buy today, but it offers a cheap share price with this new information. Shares trade at just $7.20 as of writing, up more than $2 overnight! Year to date, those shares are also up 84%, as of writing. That could soar even higher, and the potential of Big Pharma wanting a piece of the action could send this stock stratospheric.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Amy Legate-Wolfe has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

More on Investing

A bull outlined against a field
Bank Stocks

Want to Catch the Next Bull Market? Buy This Stock While It’s Still Low

You might think that buying stocks like Royal Bank of Canada before a new bull market begins is risky, but…

Read more »

Dividend Stocks

The Best Stocks to Invest $50,000 in Right Now

Canadian investors should diversify their equity portfolio by buying shares of quality companies across sectors in 2023.

Read more »

analyze data
Dividend Stocks

2 Dividend Stocks to Start Your Perfect Passive Income Portfolio

Start your passive income portfolio off on the right foot by investing in these two dividend stocks with a solid…

Read more »

oil and gas pipeline
Dividend Stocks

Is Now the Right Time to Buy TC Energy Stock?

TC Energy stock is out of favour. Is it time to buy?

Read more »

Dial moving from 4G to 5G
Dividend Stocks

TFSA Investors: Invest $3,000 for $2,150 in Income Every Year 

If you spend time in the market, you can chart out a plan to earn $2,150 in annual passive income…

Read more »

money cash dividends

Sitting on Cash: Invest $25,000 in This Dividend Stock Instead to Get $82,052 in a Decade

Here's a top dividend stock that is well worth snatching up for Canadians who have some extra cash to burn.

Read more »

Redwood trees stretch up to the sunlight.

2 Stocks With Surprising Growth Potential

Alimentation Couche-Tard and Restaurant Brands International are stealthy growth stocks that are trading too cheap right now.

Read more »

potted green plant grows up in arrow shape

2 Incredible Growth Stocks With a Bright Outlook for 2023

Constellation Software (TSX:CSU) stock and another tech titan that may be too cheap to ignore, as it looks to power…

Read more »